Ligliptin does not usually cause pancreatic islet failure. Ligliptin is a DPP-4 inhibitor, and its mechanism of action is primarily through the ability of DPP-4 to degrade enteric insulinotropic hormone-like polypeptide-1 (GLP-1) as well as glucose-dependent insulinotropic polypeptide (GIP). Riglitazide is able to elevate the concentration of active enteric insulinotropic hormone, stimulate insulin release in a glucose-dependent manner, and reduce circulating glucagon levels. Although it stimulates insulin secretion from pancreatic beta cells, it does not usually impair pancreatic function. Blood glucose should be monitored during the administration of Riglitazone, and any adverse reactions such as abdominal pain, hypersensitivity, joint pain, or edema should be seen immediately by an endocrinologist.